News & Updates
Dr. Robert Vonderheide Plans to Build Unified “Cancer Center” Across the Nation
Thursday, May 12, 2022
Robert Vonderheide was recently appointed for his second five-year term as the director of Abramson Cancer Center and the University of Pennsylvania. For the past five years, Vonderheide has been revolutionizing the care of cancer patients and innovating cancer research. New developments in live imaging of tumors during surgery and expanding radiation oncology services across Philadelphia and the greater Philadelphia area are just two of Vonderheide’s accomplishments as Director. In the next phase of his leadership, Dr. Vonderheide will build on the development of pathways to ensure that – amid the increasingly complex landscape of cancer care and research – patients across the entire health system are able to access leading-edge Penn Medicine care no matter where they live.
“Patients can expect an exceptional experience at every location across our health system – a place they are cared for by the most committed staff, specialized nurses, and top physician experts. Now, we are harmonizing that patient experience to ensure that every patient has the most seamless care and robust options across different sites of care, and the assistance to navigate easily between them,” said University of Pennsylvania Health System CEO Kevin B. Mahoney. “Under Dr. Vonderheide’s leadership, we are ensuring that every patient has every opportunity for the most personalized treatment and the very best chance at a cure through every door they enter across Penn Medicine.”
Dr. Vonderheide already has plans to continue groundbreaking research, development, and care at Abramson Cancer Center. Vonderheide wants to expand the excellence of Penn care at Abramson to patients all over, no matter where they live. New Penn locations that are planned to open this year are Proton therapy at Virtua Health in New Jersey and Lancaster General Health. Vonderheide is also expanding Abramson's telehealth by allowing patients access to Penn’s top doctors anywhere. Genetic counseling, bone marrow transplant evaluation, CAR T cell therapy, and education will all be available via telemedical this upcoming year.
Read more about Robert Vonderheide and his plans to build unified “Cancer Care” at Abramson
Picture retrieved from: https://www.pennmedicine.org/cancer/cancer-research/translating-research-to-practice
Share this post
Robert Vonderheide was recently appointed for his second five-year term as the director of Abramson Cancer Center and the University of Pennsylvania. For the past five years, Vonderheide has been revolutionizing the care of cancer patients and innovating cancer research. New developments in live imaging of tumors during surgery and expanding radiation oncology services across Philadelphia and the greater Philadelphia area are just two of Vonderheide’s accomplishments as Director. In the next phase of his leadership, Dr. Vonderheide will build on the development of pathways to ensure that – amid the increasingly complex landscape of cancer care and research – patients across the entire health system are able to access leading-edge Penn Medicine care no matter where they live.
“Patients can expect an exceptional experience at every location across our health system – a place they are cared for by the most committed staff, specialized nurses, and top physician experts. Now, we are harmonizing that patient experience to ensure that every patient has the most seamless care and robust options across different sites of care, and the assistance to navigate easily between them,” said University of Pennsylvania Health System CEO Kevin B. Mahoney. “Under Dr. Vonderheide’s leadership, we are ensuring that every patient has every opportunity for the most personalized treatment and the very best chance at a cure through every door they enter across Penn Medicine.”
Dr. Vonderheide already has plans to continue groundbreaking research, development, and care at Abramson Cancer Center. Vonderheide wants to expand the excellence of Penn care at Abramson to patients all over, no matter where they live. New Penn locations that are planned to open this year are Proton therapy at Virtua Health in New Jersey and Lancaster General Health. Vonderheide is also expanding Abramson's telehealth by allowing patients access to Penn’s top doctors anywhere. Genetic counseling, bone marrow transplant evaluation, CAR T cell therapy, and education will all be available via telemedical this upcoming year.
Read more about Robert Vonderheide and his plans to build unified “Cancer Care” at Abramson
Picture retrieved from: https://www.pennmedicine.org/cancer/cancer-research/translating-research-to-practice